Mereo BioPharma
MREO
63 hedge funds and large institutions have $24.9M invested in Mereo BioPharma in 2026 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 22 closing their positions.
69% more capital inflows, than outflows
Capital inflows: $14.5M | Capital outflows: $8.6M
49% more call options, than puts
Call options by funds: $315K | Put options by funds: $212K
8.25% more ownership
Funds ownership: 38.98% → 47.23% (+8.2%)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
10% less funds holding
Funds holding: 70 → 63 (-7)
32% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$3.51M |
| 2 |
DCM
Defilade Capital Management
Emeryville,
California
|
+$3.24M |
| 3 |
NM
Newtyn Management
New York
|
+$2.94M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$2.37M |
| 5 |
Millennium Management
New York
|
+$1.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.54M |
| 2 |
6CM
683 Capital Management
New York
|
-$1.3M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$771K |
| 4 |
UBS AM
Chicago,
Illinois
|
-$735K |
| 5 |
MAM
Monaco Asset Management
Monaco
|
-$661K |
MREO Hedge Fund Activity: Q1 2026 in Review
63 of the 8,210 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2026, worth a combined $24.9M — down 3.7% from $25.8M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of MREO and 15 opened new positions — a net loss of 7 holders — while 16 trimmed existing stakes and 15 added.
The largest buyer was Bank of America, adding an estimated $3.51M. The largest seller was Schonfeld Strategic Advisors, exiting entirely with an estimated $2.54M sold.
- 63 institutional investors held Mereo BioPharma (MREO) as of Q1 2026, down from 70 in Q4 2025.
- Funds reported $24.9M of Mereo BioPharma stock for Q1 2026, down 3.7% quarter-over-quarter.
- 15 funds opened new Mereo BioPharma positions in Q1 2026 and 22 closed out, a net change of -7 holders.
- The largest Mereo BioPharma buyer in Q1 2026 was Bank of America, an estimated $3.51M added.
- The largest Mereo BioPharma seller in Q1 2026 was Schonfeld Strategic Advisors, an estimated $2.54M sold.
Based on aggregated 13F filings for Q1 2026.